Saturday, March 10, 2012

Differentiation

How is this different?

 In ordinary medicine, the goal is to extend life (i.e. "We’ll sacrifice the quality of your existence now … for the chance of gaining time later.").

(S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid has demonstrated antineoplastic effects with all cancers tested. Independent confirmation, reproducible in-vitro dose response curves. Cell viability testing conclusively demonstrates anticancer activity of this compound. Effective against all neoplastic ATCC cell lines tested (U-87 astrocytoma, HEP G2 hepatocellular carcinoma, A 375 human malignant melanoma). This compound does not effect healthy cells (D8 LCL 'B' cells).


Since cancerous cells tend to divide at a more frequent clip than most healthy cells, they are more vulnerable to the various mechanisms in chemotherapy drugs. However, these drugs can't decipher between a healthy cell and a cancerous cell, so they kill cells indiscriminately.

Radiation destroys the immune system, especially the bone marrow that lies at the very heart of the immune system.

Due to its damage on healthy cells, chemotherapy always causes side effects, which sometimes, last a lifetime.

Cancer patients refractile to chemotherapy and radiation therapy have limited options - until now.


A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.
No anticipated 'side-effects' (e.g. 'chemo-brain', hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).
Wide therapeutic margin.
Possible primary therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.
Excellent likelihood for good stability (and thus long shelf life).
Ease of use and administration - with oral dosing possible.
Low cost of goods.
Antibiotic properties.
New 'reagent' - opens possibilities for all science.
Possible nutritional supplement usage.
  • Rapid inhibition of difficult to treat cancer cell lines.
  • Reproducible cell viability/dose response curves.
  • Mechanism consistent with activation of apoptotic pathway.
  • Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
  • Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
  • Metabolism most probably through decarboxylation.

The Science... in detail (link)



(S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid targets neoplastic (cancerous) cells. This compound does not affect 'healthy' cells - at concentrations used to kill cancerous cells. This compound kills cancer cells. Apoptosis - in neoplastic cells.
 

 



Funding and Finances - needed to finish the 'approval process' for this antineoplastic NCE:
Science advances with your help. Funding needed for CRO toxicology, IND, clinical trials.

New drugs often cost $100,000 or more a year...

 

This compound [(S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid] kills cancer cells - 









You decide!
 Stop wishing and hoping cancer away... Make it happen.


 Regards,

Dennis Wright
drwright442000@yahoo.com



Talent does what it can; Genius does what it must.                       
 Robert Bulwer-Lytton